Clinical Trials Sponsored by Prism Pharma Co., Ltd.

Total 705 results

EA Pharma Co., Ltd.
Kissei Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
TaiGen Biotechnology Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

Healthy Chinese Volunteers

China
Taizhou EOC Pharma Co., Ltd.
Fountain Medical Development Co., Ltd.

Completed

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Organon and Co
Meiji Seika Pharma Co., Ltd.

Completed

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Schizophrenia
SK Plasma Co., Ltd.

Completed

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

Korea, Republic of
SK Plasma Co., Ltd.

Completed

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

Korea, Republic of
Risen (Suzhou) Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
EA Pharma Co., Ltd.

Completed

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China
Kitasato University
Aetas Pharma Co. Ltd.

Completed

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Kukje Pharma
Samil Pharmaceutical Co., Ltd.

Completed

[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Korea, Republic of
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
Sunshine Lake Pharma Co., Ltd.
Covance

Completed

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

Idiopathic Pulmonary Fibrosis

United States
EA Pharma Co., Ltd.

Completed

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Moderate Active Ulcerative Colitis

Japan
EA Pharma Co., Ltd.

Terminated

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Primary Biliary Cholangitis

Japan
Lina Xu

Completed

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

Osteoarthritis of the Knee

United States
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Epilepsy | Partial Seizures

Japan
UCB Japan Co. Ltd.

Completed

Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males

Healthy Volunteers

Japan
SK Plasma Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation

Liver Transplantation

Korea, Republic of
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus, SLE

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Acute Ischemic Stroke

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
EA Pharma Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

Healthy Volunteers

United Kingdom
Hangzhou Zede Pharma-Tech Co., Ltd.

Completed

Short-term Clinical Study of CN128 in Thalassemia Patients

Thalassemia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

China, United States, Ukraine, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

DDI Study of Orelabrutinib

Healthy Person

China
UCB Japan Co. Ltd.

Completed

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Epilepsies | Partial

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

ADME Study of [14C]ICP-022 in Healthy Males

Healthy Volunteers

China
Tianjin XinChen-Techfields Pharma Co., LTD.

Completed

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

KNEE OSTEOARTHRITIS

China

3

Subscribe